Search Results for: cirm

Weekly reads: Vertex, stem cells for MS, Athersys, 900-day paper review at Nature

/ / 1 Comment
“While still early, these results support the continued progression of our VX-880 clinical studies, as well as future studies using our encapsulated islet cells, which hold the potential to be used without the need for immunosuppression,” said Bastiano Sanna, Ph.D., executive vice president and chief of cell and genetic therapies at Vertex.

Vertex Pharmaceuticals has a lot going for it right now on the cell therapy front. For instance, they have the strongest type 1 diabetes cell therapy pipeline after some recent acquisitions. Still it’s not a simple matter to succeed in the cell therapy space even with one therapy for one targeted disease. Trials are tough […]

Weekly reads: Vertex, stem cells for MS, Athersys, 900-day paper review at Nature Read More »

Weekly reads: RMAT jump, tissues as liquid crystals, gov stem cell advisor scammed of $650K

/ / Leave a Comment
RMAT, FDA data

The FDA has a unique mechanism called RMAT or regenerative medicine advanced therapy designation. It’s intended to move investigational regenerative therapies forward more effectively. RMAT data I recently updated The Niche RMAT list and it has jumped to 85. The FDA has approved many new RMATs this year. The data on how many applications the FDA

Weekly reads: RMAT jump, tissues as liquid crystals, gov stem cell advisor scammed of $650K Read More »

Biological age, health flexing, & stabs at rejuvenation

/ / 4 Comments
health flexing, biological age

We all know people who seem far younger than their age, which feeds into the idea of biological age. It’s often in the news these days and all over social media. Some people who are fighting high-profile battles with aging are also doing something I call “health flexing.” I also called these folks by another

Biological age, health flexing, & stabs at rejuvenation Read More »

Weekly reads: KRAS G12C, eLife journal controversy, bird iPSCs

/ / 2 Comments
KRAS mutations, KRAS G12C

If you’ve never heard of the KRAS G12C mutation, it’s a particularly frightening mutation present in numerous cancers. Like the MYC oncogene, many people view mutations in RAS as undruggable, but new efforts show some glimmers of hope. The drug Sotorasib has been approved by the FDA to target the KRAS G12C mutation. Here’s a

Weekly reads: KRAS G12C, eLife journal controversy, bird iPSCs Read More »

Weekly reads: upbeat stem cell clinical trials update, CRISPR ups & downs, story of 1st marrow transplant survivor

/ / 1 Comment
stem cell clinical trials

It’s always great to read about stem cell clinical trials that are looking encouraging. Stem cell clinical trials Proving a new therapy is safe and effective is so challenging. Remarkably, there are more than 9,300 stem cell clinical trials listed for a “stem cell” search on Clinicaltrials.gov. Of course, not all of these are actual

Weekly reads: upbeat stem cell clinical trials update, CRISPR ups & downs, story of 1st marrow transplant survivor Read More »